Targeting tertiary lymphoid structures using magneto-margination

The project aims to develop injectable superparamagnetic particles for non-invasive mapping and thermal destruction of tertiary lymphoid structures to improve diagnosis and treatment of chronic inflammation and cancer.

Subsidie
€ 1.970.480
2025

Projectdetails

Introduction

Tertiary lymphoid structures (TLS) are ectopic lymphoid tissues that drive immune responses at sites of chronic inflammation. They are of widespread interest in biology and medicine since their presence dramatically influences disease course in autoimmune disorders, infection, and cancer.

Challenges in Detection

However, due to their small size and their development in chronically altered tissues, TLS cannot be selectively targeted or detected by imaging.

Project Objectives

The current project aims at developing new methods to map and eventually destroy the TLS in a non-invasive manner.

Methodology

To this aim, a new formulation of injectable superparamagnetic particles will be produced and targeted to the TLS. A set of innovations in contrast agent design and material chemistry will be developed to dramatically increase targeting efficiency compared to existing methods.

Innovations and Technologies

By combining these innovations, intravenously injected superparamagnetic particles will accumulate in TLS in large numbers. This accumulation will allow their non-invasive detection by:

  1. Clinically available imaging modalities (magnetic resonance imaging)
  2. Emerging technologies (magnetic particle imaging)

Potential Applications

This will also open the possibility of thermal destruction of TLS using magnetic hyperthermia, providing a way to suppress a local immune response without affecting systemic immunity.

Clinical Relevance

The scientific advances and technologies of the MAGMA project will have clinically relevant applications, such as:

  • Diagnosis of chronic inflammation
  • Selection of patients for treatment with immune checkpoint inhibitors in cancer
  • Spatially selective suppression of immunity in autoimmune diseases

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.970.480
Totale projectbegroting€ 1.970.480

Tijdlijn

Startdatum1-6-2025
Einddatum31-5-2030
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • UNIVERSITE DE CAEN NORMANDIEpenvoerder

Land(en)

France

Vergelijkbare projecten binnen European Research Council

ERC Starting...

B Cell Engineering and Tertiary Lymphoid Structure Induction via Biomaterials for Cancer Immunotherapy

BeaT-IT seeks to enhance cancer immunotherapy by optimizing B cell activation and tertiary lymphoid structure formation using nano-/biomaterials for improved tumor treatment outcomes.

€ 1.488.762
ERC Consolid...

MAGNETIC HYPERTHERMIA FOR METASTASIZED TUMOR TREATMENT AND REMOTE MANIPULATION OF MICRODEVICES

The GIULIa project aims to enhance cancer treatment by using magnetic nanoparticles in natural killer cells for targeted hyperthermia and developing magnetic microdevices for precise drug delivery.

€ 2.993.750
ERC Proof of...

Focused Targeting of Inhaled Magnetic Aerosols for Lung Cancer

AEROTARG aims to enhance targeted delivery of inhaled chemotherapeutics to lung tumors using magnetically-loaded aerosols and a custom magnetic field, improving efficacy and reducing side effects.

€ 150.000
ERC Proof of...

Deep Brain Neuromodulation using Temporal Interference Magnetic Stimulation

Develop a non-invasive tool using temporal interference magnetic stimulation for precise modulation of neural activity in the brain, aiming to improve treatment options for brain disorders.

€ 150.000
ERC Synergy ...

Treating Liver Metastasis

This project aims to enhance immunotherapy for colorectal liver metastases by targeting innate immune responses, utilizing advanced models to identify key cellular interactions and functions.

€ 10.180.358

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

Ontwikkeling Tumor Lokalisatie Systeem voor Borstkanker (MaMaLoc)

Sirius Medical Systems en 3T ontwikkelen een magnetische tumor lokalisatietechniek die chirurgen helpt bij het vroegtijdig verwijderen van tumoren, met verbeterde zorg en economische groei als resultaat.

€ 84.000
EIC Transition

RESTORING IMMUNITY CONTROL OF GI CANCERS

TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.

€ 2.007.750